Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2026-06-02 Share Issue/Capital Cha…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Notification regarding unquoted securities - IMU 9 pages 25.3KB
Share Issue/Capital Change Classification · 92% confidence The document is an ASX Appendix 3G form titled “Notification of issue, conversion or payment up of unquoted equity securities,” providing details of new restricted stock units and performance rights issued under an employee incentive scheme. It is an announcement of new share issuances (capital change). According to the definitions, announcements of new share issues and capital changes are classified as SHA (Share Issue/Capital Change).
2026-06-02 English
azer-cel CAR-T naive data presented at ASCO Annual Meeting 3 pages 163.9KB
Regulatory Filings Classification · 45% confidence The document is an ASX announcement/press release about clinical data presented at a medical conference. It does not contain financial statements, shareholder vote results, capital transactions, management change disclosures, or detailed investor presentation slides. It is a general regulatory announcement of corporate news. Therefore, it best fits the fallback category Regulatory Filings (RNS).
2026-06-01 English
First Patient in BTKi Combination Cohort of azer-cel study 3 pages 210.4KB
Regulatory Filings Classification · 82% confidence The document is an ASX announcement providing a clinical trial update (first patient dosed in a BTKi combination cohort). It does not contain financial results, management changes, regulatory certifications, or detailed financial statements. It is a general corporate announcement submitted to a regulator (ASX) that does not fit other specific categories, so it falls under the catch-all Regulatory Filings (RNS) category.
2026-05-27 English
Appointment of 2 non-Executive Directors 3 pages 136.5KB
Board/Management Information Classification · 93% confidence The document is an ASX announcement titled “Imugene Announces Board Enhancement,” detailing the appointment of two new non-executive directors, their backgrounds, effective dates, and related board composition and remuneration committee actions. This is clearly an announcement of changes to the company’s board of directors, which falls under Board/Management Information.
2026-05-25 English
Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract 4 pages 205.2KB
Regulatory Filings Classification · 91% confidence The document is an ASX announcement by Imugene Limited describing clinical trial data and response rates for its CAR T therapy presented at ASCO 2026. It contains no financial statements, earnings figures, management discussion of overall results, or request for shareholder votes. It is not a full report, earnings release, proxy statement, investor presentation with slides, nor an interim or annual report. This is a miscellaneous regulatory disclosure announcing clinical data to the market, so it falls under general regulatory announcements (RNS).
2026-05-21 English
Change of Director's Interest Notice - PH 2 pages 44.8KB
Director's Dealing Classification · 90% confidence The document is an ASX Appendix 3Y "Change of Director's Interest Notice," detailing a director’s security holdings, acquisitions, disposals, and the nature of the interests. This matches a director’s personal share transactions (insider trades), which falls under the Director’s Dealing category.
2026-05-17 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.